2/24/2021

Pure Transplant Solutions Announces Collaboration with King’s College London to Support NHS Funded GAMECHANgER-1 Clinical Trial for HLA Sensitized Patients with End Stage Renal Disease

2/23/2021

Caisson Biotech, LLC & Heparinex, LLC Announce Positive Examination Report of European Patent and the Discovery of a New Class of Sugar Polymers

2/04/2021

Pure Protein, LLC and Pure Transplant Solutions, LLC Promote Blake Harlan to President and Dr. Rico Buchli to Vice President of Products and Service

1/27/2021

Pure Transplant Solutions, LLC and University Hospital Basel Announce Research Collaboration

11/30/2020

Pure Protein, LLC Announces New Website Launch Now Offering Its HLA Reagents and Technical Services to Researchers

3/20/2020

OU Health Sciences Center Partners With Pure MHC on COVID-19 Vaccine Project

3/26/2019

Hyalose, LLC Selects Echelon Biosciences, Inc. to Serve as Distributor of its Select-HA Products

1/07/2019

Emergent Technologies, Inc. Hires Steven Lloyd Mayer, MD as Chief Medical Officer and Promotes Blake Harlan to Executive Vice President Finance and Operations 

1/09/2017

Pure MHC to Partner with AbbVie on Oncology Research

1/12/2016

Emergent Technologies Company Enters into License Agreement with Xencor

9/14/2015

ETInnovation and Mymantra Srl Form Alliance To Drive Ligneah Technology

6/22/2015

ImmunoCellular Therapeutics Establishes Agreement with Pure MHC for Novel Quality Control Assay for ICT-107 Phase 3 Registrational Trial

4/8/2015

Caisson Biotech Wins Innovation Recognition Award

4/6/2015

AeonClad Coatings Announces New Patent For Method of Using Plasma Deposition

10/21/2014

PureMHC and PhosImmune Working Together On Immunotherapies for Cancer

9/8/2014

Emergent Technologies and Bledisloe & Company Enter Collaboration Agreement to Expand Technology Commercialization Opportunities

3/11/2014

Caisson Biotech Expands HEPtune™ Drug Delivery Deal with Novo Nordisk

7/24/2014

Nature Magazine – Stop the Microbial Chatter – Researchers, including those at Selenium, LTD, are looking for solutions to subvert bacterial signaling.

April 2014

AeonClad – Interactions at the Edges (Nanotech Magazine)

01/15/2013

Caisson’s Heparosan-Based Conjugates (Drug Development and Delivery)

10/26/2012

Enavail – Revving Start Up Engines (Fierce Pharma)